COVID-19 Poor Outcomes Risk Profile
Use
Assessment of patients at risk of mortality from COVID-19 disease
Special Instructions
To avoid delays in turnaround time when requesting multiple tests on frozen samples, separate frozen specimens should be submitted for each test requested. Ensure proper blood to anticoagulant ratio by filling tubes to completion and mix by gentle inversion at least six times.
Limitations
This profile may not capture all risk aspects related to COVID-19 due to variability in individual responses and other clinical variables. It is crucial to consider clinical probability assessments in conjunction with test results, especially for biomarkers like D-Dimer, where values can increase with age, potentially complicating the interpretation for venous thromboembolism exclusion.
Methodology
Automated Analyzer (Clinical Chemistry)
Biomarkers
LOINC Codes
- 14804-9
- 2276-4
- 48065-7
- 6690-2
- 789-8
- 718-7
- 4544-3
- 787-2
- 785-6
- 786-4
- 788-0
- 777-3
- 770-8
- 736-9
- 5905-5
- 713-8
- 706-2
- 75652-8
- 751-8
- 731-0
- 742-7
- 711-2
- 704-7
- 71695-1
- 53115-2
- 58413-6
- 18314-5
- N/A
- 14804-9
- 2276-4
- 48065-7
- 6690-2
- 789-8
- 718-7
- 4544-3
- 787-2
- 785-6
- 786-4
- 788-0
- 777-3
- 770-8
- 736-9
- 5905-5
- 713-8
- 706-2
- 75652-8
- 751-8
- 731-0
- 742-7
- 711-2
- 704-7
- 71695-1
- 53115-2
- 58413-6
- 18314-5
- N/A
Result Turnaround Time
1-2 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
3 mL
Minimum Volume
2 mL
Container
Gel-barrier tube
Collection Instructions
Centrifuge and carefully remove the plasma using a plastic transfer pipette, being cautious not to disturb the cells.
Storage Instructions
Room temperature